Stock Comparison

ABCL vs JNJ

Abcellera Biologics Inc vs Johnson & Johnson

The Verdict

ABCL takes this one.

Winner

ABCL

Abcellera Biologics Inc

7.2

out of 10

Solid Pick

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$1.2B

Market Cap

$557.1B

-8.0

P/E Ratio

26.5

-194.9%

Profit Margin

21.8%

-14.8%

Return on Equity

26.3%

0.1

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

7.2

DVR Score

1.0

The Deep Dive

ABCL7.2/10

AbCellera continues to hold significant 10x potential, driven by its cutting-edge AI-powered antibody discovery platform and a strategic pivot towards internal drug development. The substantial Q4 2025 revenue beat and the impending Phase 1/Phase 2 data for ABCL635 are strong positive catalysts, de-risking its pipeline and demonstrating execution. While the company still grapples with negative pro...

Full ABCL Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.